Business Context and Reporting Period
This Form 8-K is a current report filed by Ra Medical Systems, Inc. (NYSE American: RMED) on September 27, 2022. The filing primarily addresses "Other Events" (Item 8.01) regarding the ongoing merger process with Catheter Precision, Inc., a privately held medical device company focused on cardiac electrophysiology. The report also announces the appointment of Fatih Ayoglu as the Business Development Manager—EMEA for Catheter Precision.
Key Financial Metrics
This filing is a current report regarding corporate events and does not contain specific financial statements, revenue figures, profit margins, cash flow data, or debt levels for the reporting period. The document explicitly states that financial information regarding Catheter Precision and the combined entity is located in separate exhibits filed on September 12, 2022 (Exhibits 99.2 through 99.6), which are not included in this text.
Material Changes and Transaction Status
- Merger Agreement: On September 12, 2022, Ra Medical entered into an Agreement and Plan of Merger with Catheter Precision. The transaction is structured as a stock-for-stock reverse merger, where Catheter will become a wholly owned subsidiary of Ra Medical.
- Expected Closing: The merger is expected to close before the end of 2022, subject to closing conditions including shareholder approval from both companies.
- Regulatory Filings: A preliminary proxy statement was filed with the SEC on September 23, 2022. A definitive proxy statement is intended to be filed subsequently.
- Management Appointment: Fatih Ayoglu was appointed as Business Development Manager—EMEA for Catheter Precision.
Guidance, Outlook, Risks, and Contingencies
Outlook and Strategy: The combined company intends to focus on the cardiac electrophysiology market, described as a robust and growing area of medical devices. The transaction aims to leverage Catheter's product lines, including VIVO and Amigo vessel closure devices.
Key Risks and Contingencies:
- Closing Conditions: The merger is subject to conditions including a minimum prevailing stock price for Ra Medical and a specific Net Cash amount at closing. If Ra Medical's stock price drops below certain levels, the merger consideration for Catheter stockholders could be adversely impacted.
- Capital Markets: Risks exist regarding the combined company's ability to access capital markets to meet Net Cash requirements and maintain its listing on the NYSE American.
- Forward-Looking Statements: The filing includes standard disclaimers that actual results may differ materially due to uncertainties, including the ability to consummate the merger, potential delays, and the impact of the COVID-19 pandemic on economic conditions.
- Shell Company Rules: There is a risk related to the potential application of SEC and exchange "shell company" rules.
Investor Verification Checklist
- Verify the status of the Definitive Proxy Statement and the scheduled dates for the Special Meeting of Stockholders for both Ra Medical and Catheter Precision.
- Review the minimum prevailing stock price and Net Cash requirements detailed in the Merger Agreement to assess the risk of deal failure or reduced consideration.
- Examine the Pro Forma Financial Information (Exhibit 99.6 filed on September 12, 2022) to understand the projected financial position of the combined entity.
- Confirm the audited and unaudited financial statements of Catheter Precision (Exhibits 99.4 and 99.5) to evaluate the target company's standalone financial health.
- Monitor Ra Medical's stock price volatility, as it directly impacts the transaction terms and the ability to satisfy closing conditions.